Last reviewed 2026-04-20 · How we verify

Revasc (DESIRUDIN)

Revasc (Desirudin) is a small molecule anti-coagulant that targets prothrombin. It was originally developed by Marathon Pharms LLC and remains under their ownership. FDA approved in 2003 for the prevention of deep vein thrombosis, Revasc works by inhibiting the conversion of prothrombin to thrombin, thereby preventing blood clot formation. As a patented medication, its commercial status is subject to intellectual property protection. Key safety considerations include the risk of bleeding.

At a glance

Approved indications

• Prevention of deep vein thrombosis

Common side effects

No common side effects on file.

Key clinical trials

• Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization
• REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center (NA)
• Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study (NA)
• Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots (PHASE1)
• Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia (NA)
• Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia (NA)
• Community Walking Exercise for Patients With Peripheral Artery Disease (NA)
• Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery (PHASE2,PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.